TMO vs VCYT
TMO: Thermo Fisher Scientific is a global leader in serving science, providing an extensive portfolio of analytical instruments, laboratory equipment, and mission-critical consumables for the life sciences and healthcare industries. VCYT: Veracyte is a genomics-focused diagnostics company providing high-value clinical tests to improve cancer detection and treatment guidance for patients worldwide.
Side-by-side fundamentals
| Metric | TMO | VCYT | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $559.53 | $59.78 | |
| Market cap as of 2026-07-31 | $207.9B | $4.8B | |
| P/E as of 2026-07-31 | 30.20 | 55.37 | TMO lower |
| PEG as of 2026-07-31 | 2.89 | 0.32 | VCYT lower |
| Net margin as of 2026-07-31 | +15.0% | +16.3% | VCYT higher |
| Gross margin as of 2026-07-31 | +40.9% | +70.9% | VCYT higher |
| Operating margin as of 2026-07-31 | +17.6% | +15.1% | TMO higher |
| ROE as of 2026-07-31 | +13.3% | +6.9% | TMO higher |
| ROA as of 2026-07-31 | +6.3% | +6.3% | Tie |
| Debt / equity as of 2026-07-31 | 0.81 | 0.00 | VCYT lower |
| Revenue growth (YoY) as of 2026-07-31 | +7.2% | +16.9% | VCYT higher |
| Revenue CAGR (3y) SEC XBRL | -0.3% | +20.4% | VCYT higher |
| Dividend yield as of 2026-07-31 | +0.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 5 | n/a | |
| Beta as of 2026-07-31 | 0.82 | 1.39 | |
| 1-year return as of 2026-07-27 close | +17.0% | +149.4% | VCYT higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.